AbbVie cuts third-quarter guidance. AbbVie stock is valued at USD 510.7 billion
AbbVie cuts third-quarter guidance. AbbVie stock is valued at USD 510.7 billion AD HOC NEWS
Covered in this story
What has happened since
- AbbVie is down 0.1% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on AbbVie
- UBS: $276 → $275 by Oct 2027 · Neutral via GuruFocus
- Bank of America: $262 → $289 by Sep 2027 · Buy via AOL.com
- Wolfe Research: $263 → $300 by Sep 2027 · Outperform via Yahoo Finance
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $ABBV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on AbbVie →Dalsna Finance is currently tracking 48 stories mentioning AbbVie, the earliest published 22 Jun 2026.
Summary aggregated from AD HOC NEWS's public RSS feed. The full reporting belongs to AD HOC NEWS — please read it on their site.